# Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis

> **NCT07679893** · PHASE2 · RECRUITING · sponsor: **Mannkind Corporation** · enrollment: 153 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** Nintedanib Dry Powder Inhalation
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07679893
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-06
- **Target enrollment:** 153 (ESTIMATED)
- **Last updated:** 2026-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07679893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07679893, "Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07679893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*